2.51
+0.03(+1.21%)
Currency In USD
Address
Dr. Neergaards Vej
Horsholm, 2970
Denmark
Phone
45 53 53 18 50
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Mr. Christian Kanstrup M.Sc. | Chief Executive Officer | 482,000 | 1972 |
| Mr. Thomas Frederik Schmidt M.Sc. | Interim Chief Financial Officer | 77,000 | 1971 |
| Mr. Andreas Holm Mattsson | Founder & Chief AI Officer | 326,000 | 1976 |
| Dr. Birgitte Rono Ph.D. | Chief Scientific Officer | 343,000 | 1977 |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
